Category News

Production of new astrocytes contributes to an improvement in depressive and anxious behavior

The production of new astrocytes in the adult human brain may contribute to an improvement in depressive and anxious behavior in patients with neuropsychiatric diseases, as well as to the restitution of neural cells in the hippocampus, a brain region important for the control of emotional and cognitive behaviors. These are the main conclusions of a study carried out by a research team from the ICVS, and recently published in the journal Molecular Psychiatry.
Read More

ICVS Retreat 2024

More than 170 participants attended the ICVS Retreat 2024 at the Monastery of Tibães in Braga, between the 4th and 5th of July.  The program included presentations, debates, poster sessions, well-being and team building activities.
Read More

ICVS collaborates in first study on the prevalence of asthma in Portugal: more than 570 thousand people have the disease

More than 570,000 adults live with asthma in Portugal, a disease that has a prevalence of 7.1%. Of these thousands of people, almost seven in 10 (68%) do not have their disease under control, show data from “EPI-ASTHMA - Prevalence and characterization of people with asthma, according to the severity of the disease, in Portugal”, a study developed in collaboration by ICVS, CINTESIS of the University of Porto and AstraZeneca Portugal.
Read More

ICVS Researcher Vitória Baptista awarded two grants

Vitória Baptista, a PhD student in Biomedical Engineering at the Centre of Microelectromechanical Systems (CMEMS) and the Life and Health Sciences Research Institute (ICVS) at the University of Minho, has been awarded an “EMBO Scientific Exchange Grant” and a “FEMS Research and Training Grant".
Read More

Compound that aids in the digestion of fatty foods within the intestine demonstrates potential as a treatment for a rare brain disorder

In a work, recently published in the Journal of Clinical Investigation, researchers at the Life and Health Science Research Institute (ICVS) at the University of Minho, in Portugal, used animal models of spinocerebellar ataxia type 3 or Machado-Joseph disease (SCA3/MJD) to test a promising drug: the compound tauroursodeoxycholic acid (TUDCA for short).
Read More